Status: Recruiting
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients with B-cell mediated autoimmune disease.
Participants needed: 120
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Polina StepenskyUpdated: May 6, 2026Locations: 1
Eligibility criteria
Age: 18~80 years old; for patients aged ≥ 75 years, geriatric assessment and end... [+37]
CNS disease- History of CNS or spinal cord tumor, metabolic or infectious cause... [+16]